Owkin vs Regard AI

Owkin has a disclosed valuation of $1B, while Regard AI's valuation is not publicly available, making a direct size comparison difficult. Owkin employs 450 people.

Owkin has raised more in total funding at $334M, compared to Regard AI's $30M — a gap of $304M. Combined, the two companies have completed 3 known funding rounds.

Owkin holds the higher Awaira Score at 69/100, compared to Regard AI's 55/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 14-point gap that reflects meaningful differences in scale or traction.

Owkin was founded by Thomas Clozel in 2016. Regard AI's founder information is not currently available in our database.

Owkin: Owkin is a French AI healthcare company founded in 2016 that develops federated learning and privacy-preserving machine learning technologies for drug discovery and clinical research. The company operates a distributed AI platform enabling pharmaceutical companies, biotech firms, and research institutions to collaborate on data analysis without sharing sensitive patient information or proprietary datasets. Owkin's core technology utilizes federated learning, allowing multiple parties to train machine learning models collectively while maintaining data privacy and regulatory compliance, particularly under GDPR and HIPAA frameworks. The company has raised $334 million in total funding and achieved a $1.0 billion valuation, positioning it as a significant player in the intersection of AI, privacy-tech, and healthcare. Owkin operates in the Series B stage and serves pharmaceutical companies seeking to accelerate drug development through collaborative AI while preserving data confidentiality. The platform addresses a critical challenge in healthcare AI: enabling large-scale machine learning without centralizing sensitive medical data. Owkin's approach contrasts with traditional cloud-based analytics solutions by maintaining data sovereignty at source institutions. The company has established partnerships across the pharmaceutical and research sectors, though specific customer names and financial metrics remain Not disclosed. Its growth trajectory reflects expanding demand for privacy-preserving AI solutions in highly regulated healthcare markets. Owkin combines federated learning with healthcare applications, enabling collaborative AI research without compromising data privacy or regulatory compliance across distributed pharmaceutical ecosystems. Regard AI: Regard AI builds an AI clinical documentation assistant that integrates with hospital electronic health record systems to automatically identify potential diagnoses, surface relevant clinical evidence from patient records, and generate structured documentation for physician review. The system is designed to reduce the documentation burden on hospitalists and clinical teams while improving diagnostic completeness and coding accuracy.\n\nThe company raised approximately 30 million USD and has deployed across hospital systems focused on reducing physician administrative load, a problem that contributes to clinician burnout and documentation errors with downstream billing and quality implications. Regard operates as a background analysis layer that surfaces findings without requiring clinicians to change their existing EHR workflow.\n\nClinical documentation AI sits at the intersection of physician workflow optimization and revenue cycle management, giving it a dual value proposition that justifies enterprise procurement from both clinical operations and hospital finance departments. Regard competes with Nuance DAX, Abridge, and other ambient documentation tools, but its focus on diagnostic suggestion and coding completeness rather than pure transcription differentiates its clinical and financial value story.

Owkin was founded first in 2016, giving it 1 year of additional market experience. Regard AI was founded later in 2017. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Owkin has approximately 450 employees, while Regard AI has approximately 50-200. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Owkin and Regard AI are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.